AtriCure (NASDAQ:ATRC) Releases Earnings Results, Meets Expectations

AtriCure (NASDAQ:ATRC) announced its quarterly earnings data on Tuesday. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17), Briefing.com reports. The company had revenue of $116.27 million for the quarter, compared to analysts’ expectations of $116.24 million. AtriCure had a negative return on equity of 8.39% and a negative net margin of 9.33%. AtriCure’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. AtriCure updated its FY 2024 guidance to -0.820–0.740 EPS.

AtriCure Stock Down 2.5 %

NASDAQ ATRC traded down $0.53 on Thursday, hitting $21.04. The stock had a trading volume of 1,207,299 shares, compared to its average volume of 787,052. AtriCure has a 52-week low of $18.94 and a 52-week high of $57.77. The business’s fifty day moving average price is $22.64 and its 200 day moving average price is $27.02. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.00 and a quick ratio of 2.83. The stock has a market cap of $1.00 billion, a price-to-earnings ratio of -26.39 and a beta of 1.44.

Insider Activity

In other AtriCure news, insider Salvatore Privitera bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The shares were purchased at an average cost of $22.25 per share, for a total transaction of $111,250.00. Following the purchase, the insider now directly owns 103,290 shares in the company, valued at $2,298,202.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. dropped their price target on AtriCure from $34.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday. Canaccord Genuity Group cut their target price on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Stifel Nicolaus lowered their price target on shares of AtriCure from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler dropped their price objective on shares of AtriCure from $65.00 to $40.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, BTIG Research reduced their price objective on shares of AtriCure from $58.00 to $53.00 and set a “buy” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.44.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.